Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy; SB-525 Was Well Tolerated And Demonstrated A Dose-Dependent Increase In Factor VIII (FVIII) Levels
Benzinga Newsdesk